TreeFrog Therapeutics is a French-based biotech company aiming to provide access to safe and affordable cell therapies for millions of patients.
Using proprietary C-StemTM technology, TreeFrog Therapeutics announced in April 2021 the production of a single batch of 15 billion human induced pluripotent stem cells (hiPSC) in a 10L bioreactor with an unprecedented expansion factor of 276x per week.
Biomimetic C-StemTM technology – which overcomes current bottlenecks in cell therapy manufacturing regarding scalability and costs – also introduces :
- A new quality standard for hiPSC-derived cell products, with preservation of genomic integrity at scale
- Ready-to-transplant hiPSC-derived 3D microtissues, for faster time to effect and improved safety
Developing a pipeline of cell therapies with mass-market potential addressing neurodegenerative disorders, cardiac and metabolic diseases, as well as blood and immune disorders, TreeFrog Therapeutics is currently setting up technological hubs in Boston, USA, and in Japan to establish novel co-development partnerships.